Cargando…
Induction Chemotherapy Improved Long-term Outcomes of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Analysis of 5-year Survival Outcomes in the Era of Intensity-modulated Radiotherapy
Background: The aim of this study is to evaluate the long-term therapeutic gain of induction chemotherapy (IC) in locoregionally advanced nasopharyngeal carcinoma (NPC) in the era of intensity-modulated radiotherapy (IMRT). Methods: Data on 957 patients with stage T1-2N2-3 or T3-4N1-3 NPC treated wi...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332887/ https://www.ncbi.nlm.nih.gov/pubmed/28261337 http://dx.doi.org/10.7150/jca.16732 |
_version_ | 1782511614246780928 |
---|---|
author | Peng, Hao Chen, Lei Zhang, Jian Li, Wen-Fei Mao, Yan-Ping Zhang, Yuan Liu, Li-Zhi Tian, Li Lin, Ai-Hua Sun, Ying Ma, Jun |
author_facet | Peng, Hao Chen, Lei Zhang, Jian Li, Wen-Fei Mao, Yan-Ping Zhang, Yuan Liu, Li-Zhi Tian, Li Lin, Ai-Hua Sun, Ying Ma, Jun |
author_sort | Peng, Hao |
collection | PubMed |
description | Background: The aim of this study is to evaluate the long-term therapeutic gain of induction chemotherapy (IC) in locoregionally advanced nasopharyngeal carcinoma (NPC) in the era of intensity-modulated radiotherapy (IMRT). Methods: Data on 957 patients with stage T1-2N2-3 or T3-4N1-3 NPC treated with IMRT were retrospectively reviewed. Propensity score matching (PSM) method was adopted to balance influence of various covariates. Patient survival between IC and non-IC groups were compared. Results: For the 318 pairs selected from the original 957 patients by PSM, the median follow-up duration was 57.13 months (range, 1.27-78.1 months). The 5-year overall survival (OS), distant metastasis-free survival (DMFS), disease-free survival (DFS) and locoregional relapse-free survival (LRRFS) rates for IC group vs. non-IC group were 87.2% vs. 80.8% (P = 0.023), 88.1% vs. 83.2% (P = 0.071), 80.7% vs. 71.4% (P = 0.011) and 92.1% vs. 86.7% (P = 0.081), respectively. Multivariate analysis identify IC as an independent prognostic factor for OS (HR, 0.595; 95% CI, 0.397-0.891; P = 0.012) and DFS (HR, 0.627; 95% CI, 0.451-0.872; P = 0.006). After excluding the patients not receiving concurrent chemotherapy, IC was found to be an independent prognostic factor for OS (HR, 0.566; 95% CI, 0.368-0.872; P = 0.01), DMFS (HR, 0.580; 95% CI, 0.367-0.916; P = 0.02) and DFS (HR, 0.633; 95% CI, 0.444-0.903; P = 0.012). Conclusions: IC is an effective treatment modality for patients with stage T1-2N2-3 and T3-4N1-3 NPC, and the incorporation of IC with standard CCRT could achieve the best therapeutic gain. |
format | Online Article Text |
id | pubmed-5332887 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-53328872017-03-03 Induction Chemotherapy Improved Long-term Outcomes of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Analysis of 5-year Survival Outcomes in the Era of Intensity-modulated Radiotherapy Peng, Hao Chen, Lei Zhang, Jian Li, Wen-Fei Mao, Yan-Ping Zhang, Yuan Liu, Li-Zhi Tian, Li Lin, Ai-Hua Sun, Ying Ma, Jun J Cancer Research Paper Background: The aim of this study is to evaluate the long-term therapeutic gain of induction chemotherapy (IC) in locoregionally advanced nasopharyngeal carcinoma (NPC) in the era of intensity-modulated radiotherapy (IMRT). Methods: Data on 957 patients with stage T1-2N2-3 or T3-4N1-3 NPC treated with IMRT were retrospectively reviewed. Propensity score matching (PSM) method was adopted to balance influence of various covariates. Patient survival between IC and non-IC groups were compared. Results: For the 318 pairs selected from the original 957 patients by PSM, the median follow-up duration was 57.13 months (range, 1.27-78.1 months). The 5-year overall survival (OS), distant metastasis-free survival (DMFS), disease-free survival (DFS) and locoregional relapse-free survival (LRRFS) rates for IC group vs. non-IC group were 87.2% vs. 80.8% (P = 0.023), 88.1% vs. 83.2% (P = 0.071), 80.7% vs. 71.4% (P = 0.011) and 92.1% vs. 86.7% (P = 0.081), respectively. Multivariate analysis identify IC as an independent prognostic factor for OS (HR, 0.595; 95% CI, 0.397-0.891; P = 0.012) and DFS (HR, 0.627; 95% CI, 0.451-0.872; P = 0.006). After excluding the patients not receiving concurrent chemotherapy, IC was found to be an independent prognostic factor for OS (HR, 0.566; 95% CI, 0.368-0.872; P = 0.01), DMFS (HR, 0.580; 95% CI, 0.367-0.916; P = 0.02) and DFS (HR, 0.633; 95% CI, 0.444-0.903; P = 0.012). Conclusions: IC is an effective treatment modality for patients with stage T1-2N2-3 and T3-4N1-3 NPC, and the incorporation of IC with standard CCRT could achieve the best therapeutic gain. Ivyspring International Publisher 2017-02-10 /pmc/articles/PMC5332887/ /pubmed/28261337 http://dx.doi.org/10.7150/jca.16732 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Peng, Hao Chen, Lei Zhang, Jian Li, Wen-Fei Mao, Yan-Ping Zhang, Yuan Liu, Li-Zhi Tian, Li Lin, Ai-Hua Sun, Ying Ma, Jun Induction Chemotherapy Improved Long-term Outcomes of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Analysis of 5-year Survival Outcomes in the Era of Intensity-modulated Radiotherapy |
title | Induction Chemotherapy Improved Long-term Outcomes of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Analysis of 5-year Survival Outcomes in the Era of Intensity-modulated Radiotherapy |
title_full | Induction Chemotherapy Improved Long-term Outcomes of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Analysis of 5-year Survival Outcomes in the Era of Intensity-modulated Radiotherapy |
title_fullStr | Induction Chemotherapy Improved Long-term Outcomes of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Analysis of 5-year Survival Outcomes in the Era of Intensity-modulated Radiotherapy |
title_full_unstemmed | Induction Chemotherapy Improved Long-term Outcomes of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Analysis of 5-year Survival Outcomes in the Era of Intensity-modulated Radiotherapy |
title_short | Induction Chemotherapy Improved Long-term Outcomes of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Analysis of 5-year Survival Outcomes in the Era of Intensity-modulated Radiotherapy |
title_sort | induction chemotherapy improved long-term outcomes of patients with locoregionally advanced nasopharyngeal carcinoma: a propensity matched analysis of 5-year survival outcomes in the era of intensity-modulated radiotherapy |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332887/ https://www.ncbi.nlm.nih.gov/pubmed/28261337 http://dx.doi.org/10.7150/jca.16732 |
work_keys_str_mv | AT penghao inductionchemotherapyimprovedlongtermoutcomesofpatientswithlocoregionallyadvancednasopharyngealcarcinomaapropensitymatchedanalysisof5yearsurvivaloutcomesintheeraofintensitymodulatedradiotherapy AT chenlei inductionchemotherapyimprovedlongtermoutcomesofpatientswithlocoregionallyadvancednasopharyngealcarcinomaapropensitymatchedanalysisof5yearsurvivaloutcomesintheeraofintensitymodulatedradiotherapy AT zhangjian inductionchemotherapyimprovedlongtermoutcomesofpatientswithlocoregionallyadvancednasopharyngealcarcinomaapropensitymatchedanalysisof5yearsurvivaloutcomesintheeraofintensitymodulatedradiotherapy AT liwenfei inductionchemotherapyimprovedlongtermoutcomesofpatientswithlocoregionallyadvancednasopharyngealcarcinomaapropensitymatchedanalysisof5yearsurvivaloutcomesintheeraofintensitymodulatedradiotherapy AT maoyanping inductionchemotherapyimprovedlongtermoutcomesofpatientswithlocoregionallyadvancednasopharyngealcarcinomaapropensitymatchedanalysisof5yearsurvivaloutcomesintheeraofintensitymodulatedradiotherapy AT zhangyuan inductionchemotherapyimprovedlongtermoutcomesofpatientswithlocoregionallyadvancednasopharyngealcarcinomaapropensitymatchedanalysisof5yearsurvivaloutcomesintheeraofintensitymodulatedradiotherapy AT liulizhi inductionchemotherapyimprovedlongtermoutcomesofpatientswithlocoregionallyadvancednasopharyngealcarcinomaapropensitymatchedanalysisof5yearsurvivaloutcomesintheeraofintensitymodulatedradiotherapy AT tianli inductionchemotherapyimprovedlongtermoutcomesofpatientswithlocoregionallyadvancednasopharyngealcarcinomaapropensitymatchedanalysisof5yearsurvivaloutcomesintheeraofintensitymodulatedradiotherapy AT linaihua inductionchemotherapyimprovedlongtermoutcomesofpatientswithlocoregionallyadvancednasopharyngealcarcinomaapropensitymatchedanalysisof5yearsurvivaloutcomesintheeraofintensitymodulatedradiotherapy AT sunying inductionchemotherapyimprovedlongtermoutcomesofpatientswithlocoregionallyadvancednasopharyngealcarcinomaapropensitymatchedanalysisof5yearsurvivaloutcomesintheeraofintensitymodulatedradiotherapy AT majun inductionchemotherapyimprovedlongtermoutcomesofpatientswithlocoregionallyadvancednasopharyngealcarcinomaapropensitymatchedanalysisof5yearsurvivaloutcomesintheeraofintensitymodulatedradiotherapy |